Clinical Trial

Efficacy and Safety of Mirabegron Versus Oxybutynin After Posterior Urethral Valve Ablation

Completed
View on ClinicalTrials.gov →
Summary
Posterior urethral valve is the main cause of bladder outlet obstruction in male infants and the most common cause of obstructive uropathy leading to chronic renal failure and end-stage renal disease in children.The incidence of posterior urethral valve is approximately 1:7,000-8,000 live births.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-19.
Trial Details
NCT Number NCT07668232
Lead Sponsor South Valley University
Conditions Posterior Urethral Valve
Enrollment 52 participants
Start Date 2025-01-01
Primary Completion 2025-12-15 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-29